Immunological equivalence between mouse brain-derived and Vero cell-derived Japanese encephalitis vaccines

Motoharu Abe, Kouichi Shiosaki, Lena Hammar, Kengo Sonoda, Li Xing, Syoji Kuzuhara, Yoichiro Kino, R. Holland Cheng

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


The persistent spread via animal reservoirs urges expanding vaccination programs against pathogens like the Japanese encephalitis virus, JEV. The JEV is spreads to new areas by domestic as well as by wild animals. Although there is a safe and efficient vaccine on the market, this is derived from infected mouse brains, why today's situation requires overcoming the potential risk caused by using animal tissues. To meet this demand we have developed a Vero cell-derived JEV vaccine, using the same virus strain as in the established one. A phase III clinical study of the new vaccine has recently been completed with positive outcome. Like the established mouse brain-derived vaccine, the Vero cell-derived one is a formalin inactivated whole virus vaccine. We here demonstrate the very good agreement in immunological tests between the two antigens. The study includes analyses with two neutralizing monoclonal antibodies that blocks cell entry at a late stage in infection, assumedly interfering with fusion-related refolding in the virus fusion protein. It is obvious that the formalin inactivation treatment, with both virus preparations, retains these essential vaccine epitopes.

Original languageEnglish (US)
Pages (from-to)152-160
Number of pages9
JournalVirus Research
Issue number2
StatePublished - Nov 2006


  • Cell system derived whole virus vaccine
  • Fusion protein refolding
  • Japanese encephalitis
  • Neutralizing antibodies

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Virology


Dive into the research topics of 'Immunological equivalence between mouse brain-derived and Vero cell-derived Japanese encephalitis vaccines'. Together they form a unique fingerprint.

Cite this